A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a pilot study that will evaluate disease status in children that have been newly
diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the
medication (Larotrectinib) have been given.
The study will also evaluate the safety of larotrectinib when given with chemotherapy in your
children; as well as the safety larotrectinib when given post-focal radiation therapy.